A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer.
Link
C J
CJ
Moorman
D
D
Seregina
T
T
Levy
J P
JP
Schabold
K J
KJ
D000293:Adolescent; D000328:Adult; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004992:Ethics, Medical; D005260:Female; D015774:Ganciclovir / Q000009:adverse effects / Q000627:therapeutic use*; D005814:Genes, Viral; D015316:Genetic Therapy / Q000009:adverse effects; D006561:Herpes Simplex / Q000201:enzymology / Q000235:genetics*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D010051:Ovarian Neoplasms / Q000628:therapy*; D018579:Patient Selection; D011446:Prospective Studies; D018570:Risk Assessment; D013937:Thymidine Kinase / Q000235:genetics*; D016896:Treatment Outcome
D013937:Thymidine Kinase; D015774:Ganciclovir